Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach
Background: The rapid advancement of the pandemic caused by SARS-CoV-2 and its variants reinforced the importance of developing easy-to-edit vaccines with fast production, such as multi-epitope DNA vaccines. The present study aimed to construct a synthetic antigen multi-epitope SARS-CoV-2 to produce...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/2/149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718776567693312 |
|---|---|
| author | Maria da Conceição Viana Invenção Larissa Silva de Macêdo Ingrid Andrêssa de Moura Lucas Alexandre Barbosa de Oliveira Santos Benigno Cristofer Flores Espinoza Samara Sousa de Pinho Lígia Rosa Sales Leal Daffany Luana dos Santos Bianca de França São Marcos Carolina Elsztein Georon Ferreira de Sousa Guilherme Antonio de Souza-Silva Bárbara Rafaela da Silva Barros Leonardo Carvalho de Oliveira Cruz Julliano Matheus de Lima Maux Jacinto da Costa Silva Neto Cristiane Moutinho Lagos de Melo Anna Jéssica Duarte Silva Marcus Vinicius de Aragão Batista Antonio Carlos de Freitas |
| author_facet | Maria da Conceição Viana Invenção Larissa Silva de Macêdo Ingrid Andrêssa de Moura Lucas Alexandre Barbosa de Oliveira Santos Benigno Cristofer Flores Espinoza Samara Sousa de Pinho Lígia Rosa Sales Leal Daffany Luana dos Santos Bianca de França São Marcos Carolina Elsztein Georon Ferreira de Sousa Guilherme Antonio de Souza-Silva Bárbara Rafaela da Silva Barros Leonardo Carvalho de Oliveira Cruz Julliano Matheus de Lima Maux Jacinto da Costa Silva Neto Cristiane Moutinho Lagos de Melo Anna Jéssica Duarte Silva Marcus Vinicius de Aragão Batista Antonio Carlos de Freitas |
| author_sort | Maria da Conceição Viana Invenção |
| collection | DOAJ |
| description | Background: The rapid advancement of the pandemic caused by SARS-CoV-2 and its variants reinforced the importance of developing easy-to-edit vaccines with fast production, such as multi-epitope DNA vaccines. The present study aimed to construct a synthetic antigen multi-epitope SARS-CoV-2 to produce a DNA vaccine. Methods: A database of previously predicted Spike and Nucleocapsid protein epitopes was created, and these epitopes were analyzed for immunogenicity, conservation, population coverage, and molecular docking. Results: A synthetic antigen with 15 epitopes considered immunogenic, conserved even in the face of variants and that were able to anchor themselves in the appropriate HLA site, together had more than 90% worldwide coverage. A multi-epitope construct was developed with the sequences of these peptides separated from each other by linkers, cloned into the pVAX1 vector. This construct was evaluated in vivo as a DNA vaccine and elicited T CD4+ and T CD8+ cell expansion in the blood and spleen. In hematological analyses, there was an increase in lymphocytes, monocytes, and neutrophils between the two doses. Furthermore, based on histopathological analysis, the vaccines did not cause any damage to the organs analyzed. Conclusions: The present study generated a multi-epitope synthetic vaccine antigen capable of generating antibody-mediated and cellular immune responses. |
| format | Article |
| id | doaj-art-528cce0b048e4aee96b5653dc5d82c5d |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-528cce0b048e4aee96b5653dc5d82c5d2025-08-20T03:12:16ZengMDPI AGVaccines2076-393X2025-01-0113214910.3390/vaccines13020149Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo ApproachMaria da Conceição Viana Invenção0Larissa Silva de Macêdo1Ingrid Andrêssa de Moura2Lucas Alexandre Barbosa de Oliveira Santos3Benigno Cristofer Flores Espinoza4Samara Sousa de Pinho5Lígia Rosa Sales Leal6Daffany Luana dos Santos7Bianca de França São Marcos8Carolina Elsztein9Georon Ferreira de Sousa10Guilherme Antonio de Souza-Silva11Bárbara Rafaela da Silva Barros12Leonardo Carvalho de Oliveira Cruz13Julliano Matheus de Lima Maux14Jacinto da Costa Silva Neto15Cristiane Moutinho Lagos de Melo16Anna Jéssica Duarte Silva17Marcus Vinicius de Aragão Batista18Antonio Carlos de Freitas19Laboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Genetics and Biotechnology (GMBio), Department of Biology, Center for Biological and Health Sciences, Federal University of Sergipe, São Cristóvão 49100-000, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Cytological and Molecular Research, Department of Histology and Embriology, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Cytological and Molecular Research, Department of Histology and Embriology, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilLaboratory of Molecular Genetics and Biotechnology (GMBio), Department of Biology, Center for Biological and Health Sciences, Federal University of Sergipe, São Cristóvão 49100-000, BrazilLaboratory of Molecular Studies and Experimental Therapy—LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, BrazilBackground: The rapid advancement of the pandemic caused by SARS-CoV-2 and its variants reinforced the importance of developing easy-to-edit vaccines with fast production, such as multi-epitope DNA vaccines. The present study aimed to construct a synthetic antigen multi-epitope SARS-CoV-2 to produce a DNA vaccine. Methods: A database of previously predicted Spike and Nucleocapsid protein epitopes was created, and these epitopes were analyzed for immunogenicity, conservation, population coverage, and molecular docking. Results: A synthetic antigen with 15 epitopes considered immunogenic, conserved even in the face of variants and that were able to anchor themselves in the appropriate HLA site, together had more than 90% worldwide coverage. A multi-epitope construct was developed with the sequences of these peptides separated from each other by linkers, cloned into the pVAX1 vector. This construct was evaluated in vivo as a DNA vaccine and elicited T CD4+ and T CD8+ cell expansion in the blood and spleen. In hematological analyses, there was an increase in lymphocytes, monocytes, and neutrophils between the two doses. Furthermore, based on histopathological analysis, the vaccines did not cause any damage to the organs analyzed. Conclusions: The present study generated a multi-epitope synthetic vaccine antigen capable of generating antibody-mediated and cellular immune responses.https://www.mdpi.com/2076-393X/13/2/149vaccinologyimmunoinformaticsvariants |
| spellingShingle | Maria da Conceição Viana Invenção Larissa Silva de Macêdo Ingrid Andrêssa de Moura Lucas Alexandre Barbosa de Oliveira Santos Benigno Cristofer Flores Espinoza Samara Sousa de Pinho Lígia Rosa Sales Leal Daffany Luana dos Santos Bianca de França São Marcos Carolina Elsztein Georon Ferreira de Sousa Guilherme Antonio de Souza-Silva Bárbara Rafaela da Silva Barros Leonardo Carvalho de Oliveira Cruz Julliano Matheus de Lima Maux Jacinto da Costa Silva Neto Cristiane Moutinho Lagos de Melo Anna Jéssica Duarte Silva Marcus Vinicius de Aragão Batista Antonio Carlos de Freitas Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach Vaccines vaccinology immunoinformatics variants |
| title | Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach |
| title_full | Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach |
| title_fullStr | Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach |
| title_full_unstemmed | Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach |
| title_short | Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach |
| title_sort | design and immune profile of multi epitope synthetic antigen vaccine against sars cov 2 an in silico and in vivo approach |
| topic | vaccinology immunoinformatics variants |
| url | https://www.mdpi.com/2076-393X/13/2/149 |
| work_keys_str_mv | AT mariadaconceicaovianainvencao designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT larissasilvademacedo designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT ingridandressademoura designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT lucasalexandrebarbosadeoliveirasantos designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT benignocristoferfloresespinoza designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT samarasousadepinho designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT ligiarosasalesleal designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT daffanyluanadossantos designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT biancadefrancasaomarcos designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT carolinaelsztein designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT georonferreiradesousa designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT guilhermeantoniodesouzasilva designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT barbararafaeladasilvabarros designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT leonardocarvalhodeoliveiracruz designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT jullianomatheusdelimamaux designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT jacintodacostasilvaneto designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT cristianemoutinholagosdemelo designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT annajessicaduartesilva designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT marcusviniciusdearagaobatista designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach AT antoniocarlosdefreitas designandimmuneprofileofmultiepitopesyntheticantigenvaccineagainstsarscov2aninsilicoandinvivoapproach |